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ABSTRACT
Objective: The purpose of this study was to determine if the prevalence of neonatal and maternal
infectious morbidity in patients with preterm premature rupture of membranes (PROM) who
received ampicillin prophylaxis for presemptive group B streptococcal colonization is increased
compared to those who received no prophylaxis.
Methods: The charts of all patients with preterm PROM who delivered between January 1988
and December 1993 were retrospectively reviewed. The routine use of ampicillin prophylaxis was
initiated in January 1991. Patients with singleton gestations were included in the analysis only if
chorioamnionitis was excluded on admission. Variables used in the final analysis included gesta-
tional age at the time of preterm PROM, gestational age at delivery, duration of rupture of mem-
branes, birth weight, method of delivery, use of steroids, tocolytics, or antibiotics for group B
streptococcus prophylaxis, neonatal sepsis, neonatal mortality, and postpartum endomyometritis.
Data were analyzed using Student’s t-test, chi-square test, Fisher’s exact test, and stepwise logistic
regression analysis to evaluate the effect of chemoprophylaxis for group B streptococcus on the
incidence of neonatal sepsis and maternal postpartum endomyometritis. A two-tailed P < 0.05 was
used to denote statistical significance.
Results: The charts of 206 patients were reviewed; 146 patients received ampicillin for group B
streptococcal prophylaxis and 60 patients did not. There was a significantly higher incidence of
postpartum endomyometritis among the patients who received ampicillin (62% vs. 22%; P < 0.01).
The association between postpartum endomyometritis and chemoprophylaxis remained significant
even after controlling for other confounding variables. There was no significant difference in the
incidence ofneonatal sepsis (5% vs. 7%; P 0.7) or death (5% vs. 3%; P 0.9) between both groups.
Conclusions: Group B streptococcal prophylaxis with a short course of intravenous ampicillin
increases the risk of postpartum endomyometritis in patients with premature PROM. Infect. Dis.
Obstet. Gynecol. 4:313-318, 1996. (C) 1997 Wiley-Liss, Inc.
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he goal of the physician managing a patient
with preterm premature rupture of the mem-
branes (PROM) is to minimize the risks of both
respiratory distress syndrome and maternal and
neonatal infection. The etiology of preterm PROM
is, however, poorly understood. There is evidence
suggesting that an inflammatory process from ei-
ther a local ascending vaginal or intra-amniotic bac-
terial infection may weaken the membranes, thus
leading to membrane rupture. This has led to nu-
merous trials utilizing antibiotic prophylaxis in pa-
tients with preterm PROM.z-6 However, there is
no consensus in the literature regarding the choice
of antibiotic or the duration of therapy that should
be undertaken.
Group B streptococcus has been shown to be a
risk factor for the development of preterm PROM,
neonatal infection, and postpartum febrile morbid-
ity. 1,7,8 Numerous studies have shown a reduction
in the incidence of early-onset neonatal group B
streptococcal disease after maternal antibiotic che-
moprophylaxis.9-1z These studies have led both
the American College of Obstetricians and Gyne-
cologists (ACOG) 1" and the American Academy of
Pediatrics (AAP) 14 to recommend treatment with
either penicillin or ampicillin in patients with un-
known status for group B streptococcal colonization
who are intrapartum with preterm PROM. Since in
most centers the majority of patients would fall into
this category, these recommendations would lead
to the use of anbibiotics in a large number of pa-
tients with preterm PROM. Neither college, how-
ever, has defined the duration of therapy in a pa-
tient who remains undelivered. The purpose of
this study was to determine if the prevalence of
neonatal and maternal infectious morbidity in pa-
tients with preterm PROM who received ampicil-
lin prophylaxis for presumptive group B streptococ-
cal colonization is increased compared to those who
received no prophylaxis.
SUBJECTS AND METHODS
The records of all patients with preterm PROM
admitted prior to 37 weeks of gestation to the Bay-
lor Perinatal Service at St. Luke’s Episcopal Hos-
pital between January 1989 and December 1993
were reviewed. These patients were all referred to
the Baylor Perinatal Service by private physicians
and copies of their records were maintained both at
St. Luke’s Episcopal Hospital and at the Baylor
Perinatal Service offices. PROM was documented
by the presence of obvious pooling or fern and
nitrazine-positive fluid in the posterior fornix on
sterile speculum examination. Patients with single-
ton gestations were included in the analysis only if
chorioamnionitis was excluded on admission (oral
temperature <100.4F and no evidence of uterine
tenderness, fetal tachycardia, or foul smelling vagi-
nal discharge), and the patient was confined to con-
servative management without active intervention.
Conservative management consisted of bed rest,
twice weekly biophysical profiles, and external fe-
tal heart rate monitoring 3 times daily. The best
estimate of gestational age was determined on ad-
mission using menstrual history, prenatal records,
and ultrasound criteria.
A policy of routine chemoprophylaxis for group
B streptococcus was initiated in January 1991. Prior
to this time, chemoprophylaxis was administered
based on the individual physician’s index of suspi-
cion or findings on Gram stain of cervical culture.
After this time, all patients with preterm PROM
managed conservatively were given intravenous
ampicillin (2 g bolus, followed by g every 4 h)
until the result of the anogenital cultures for group
B streptococcus became available (usually within
48-72 h). All cultures were obtained via culturette
from the cervix, lower third of the vagina, and the
anus. The culture swabs were transported to the
laboratory where they were inoculated within 2 h
on both blood agar plates and Todd-Hewitt broth.
These were then incubated for 18-24 h. If the cul-
ture was positive, the patient was given amoxicillin
500 mg orally every 8 h to complete a total of 10
days of antibiotic therapy. Intravenous antibiotics
were discontinued if the culture returned negative.
Patients allergic to penicillin were given cefoxitin
g intravenously every 6 h. Tocolytics were used
according to the discretion of the treating physi-
cian. Antenatal steroids to enhance fetal lung ma-
turity were not routinely used during this time pe-
riod. Cervical evaluations were performed visually
by sterile speculum examination, while digital ex-
aminations were reserved for patients in active la-
bor. Labor was induced if a non-reassuring fetal
heart rate pattern was documented on the elec-
tronic fetal heart monitoring, intra-amniotic infec-
tion was evident, or patients attained a gestational
age of 36 weeks. Diagnosis of intra-amniotic infec-
tion was based on maternal fever, maternal or fetal
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tachycardia, uterine tenderness, foul odor of amni-
otic fluid, and leukocytosis. All patients were re-
started on ampicillin intravenously once labor was
induced.
Neonatal sepsis was defined as positive blood
cultures. The patient was considered to have de-
veloped postpartum endomyomctritis if the pri-
mary physican documented uterine tenderness to
clinical examination and leukocytosis in conjunc-
tion with an oral temperature > 100.4F on at least
2 occasions 6 h apart. Endometrial and anogcnital
cultures were not routinely performed on patients
developing endomyometritis.
Variables used in the final analysis included
gcstational age at the time of preterm PROM
(GApRoM), gestational age at delivery (GAtEI),
length of the latency period (defined as the in-
terval between membrane rupture and delivery,
PROMIAW), birth weight (BW), delivery method
(vaginal vs. cesarean section), use of antibiotics for
group B streptococcal prophylaxis, steroids or toco-
lyrics, neonatal sepsis, neonatal mortality, and post-
partum endomyometritis.
The data were analyzed using Student’s chi-
square test, or Fisher’s exact test as appropriate.
The D’Agostino test was used to check for nor-
malcy of distribution of the data sets. A stepwise
logistic regression analysis was used to eva:luate the
effect of group B streptococcal chemoprophylaxis
on the incidence of neonatal sepsis and maternal
postpartum endomyometritis after controlling for
other confounding variables. A two-tailed P < 0.05
was used to denote statistical significance.
RESULTS
The charts of 206 patients with preterm PROM
were reviewed. A total of 146 patients received
chemoprophylaxis; 60 patients did not receive pro-
phylaxis. Seven patients received chemoprophy-
laxis prior to January 1991 with only developing
postpartum endomyometritis. No patients received
cefoxitin. There was a 25% prevalence of group B
streptococcus at initial culture. Table compares
the demographic characteristics of the two groups.
There was no significant difference in the inci-
dence of neonatal sepsis (5% vs. 7%; P 0.7) or
death (5% vs. 3%; P 0.9) between patients who
received antibiotic prophylaxis and those who did
not. There was a significantly higher incidence of
postpartum endomyometritis in patients who re-
TABLE I. Demographic data
Ampicillin No ampicillin
(n 146) (n 60)
GApRoM (weeks) 29.9 + 3.2 30.7 + 3.2 NS
GApE (weeks) 31.2 + 2.9 31.7 + 2.9 NS
PROM,AT (days) 9 + 12 7 + 10 NS
BW (g) 1,694 + 557 1,836 _+ 586 NS
Vaginal delivery 95 (65) 44 (73) NS
Received steroids 12 (8) 3 (5) NS
Received tocolytics 77 (53) 33 (55) NS
Neonatal sepsis 8 (5) 4 (7) NS
Neonatal death 7 (5) 2 (3) NS
Postpartum endo-
myometritis 90 (62) 13 (22) <0.01
aMean + standard deviation or number (%). NS, not significant.
ccived prophylaxis (62% vs. 22%; P < 0.01). The
latency period was similar in both groups (9 vs. 7
days; P 0.3).
Table 2 summarizes the univariate analysis of
risk factors for developing neonatal sepsis. Neo-
nates who developed sepsis had a significantly
lower birth weight and gestational age at PROM
and delivery compared to those who did not. The
latency period and the number of patients who de-
livered vaginally, received antibiotic prophylaxis,
tocolytics, or steroids were not significantly differ-
ent between the two groups. Group B streptococ-
cus sensitive to ampicillin was isolated from 4 neo-
nates developing neonatal sepsis (2 in each group).
Escherichia coli and Staphylococcus aureus, which
were resistant to ampicillin, were isolated among
the remainder.
Patients diagnosed with postpartum endomyo-
metritis had a lower gestational age at delivery and
birth weight (Table 3). They were significantly
more likely to have been delivered by cesarean
section and to have received group B streptococcal
prophylaxis. The latency period and the number of
patients receiving tocolytics or steroids, however,
were not significantly different between those who
developed postpartum endomyometritis and those
who did not.
Of the patients with vaginal delivery, endomyo-
metritis developed in 47% with vs. 7% without an-
tibiotic prophylaxis (P < 0.01). Of the patients de-
livering by cesarean section, endomyometritis de-
veloped in 88% with vs. 63% without antibiotic
prophylaxis (P < 0.04). However, the association
between postpartum endomyometritis and ampicil-
lin remained significant even after controlling for
gestational age at delivery, birth weight, adminis-
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TABLE 2. Univariate analysis of risk factors for neonatal sepsis
Sepsis No sepsis
(n 12) (n 194) Odds ratio 95% CI
GApRoM (weeks) 27.9 +/- 3.3 30.3 + 3.
GADE (weeks) 29.4 +/- 2.8 31.5 + 2.9
PROMAT (days) II +/- 12 8 + 12
BW (g) 1,377 + 459 1,758 +/- 568
Vaginal delivery 6 (50) 133 (69) 0.50
Received steroids (8) 14 (7) 1.20
Received tocolytics 5 (42) 105 (54) 0.60
Received ampicillin 8 (67) 138 (71) 0.80
0.5-4.2
0.4-3.8
-1.3-0.7
50.3-710.
0.1-1.7
0.1-10.0
0.2-2.2
0.2-3.4
0.03
0.02
NS
0.02
NS
NS
NS
NS
aMean + standard deviation or number (%). NS, not significant; CI, confidence interval.
TABLE 3. Univariate analysis of risk factors for postpartum endomyometritis
No
Endomyometritis endomyometritis
(n 103) (n 103) Odds ratio 95% CI
GApRoM (weeks) 29.8 +/- 3.0 30.5 + 3.3
GApE (weeks) 30.9 + 3. 31.9 +/- 2.7
PROMv (days) 8 + 10 10 +/- 13
BW (g) 1,654 +/- 595 1,816 +/- 531
Cesarean section 55 (53) 12 (12)
Received steroids 8 (8) 7 (7)
Received tocolytics 62 (60) 48 (47)
Received ampicillin 90 (87) 56 (54)
8.69
1.15
1.70
5.80
0.2-1.6
-1.8--0.2
-0.7-0.2
7.9-317.8
4.0-19.0
0.4-3.7
0.9-3.
2.8-12.5
NS
0.02
NS
0.04
0.01
NS
NS
0.01
aMean + standard deviation or number (%). NS, not significant; CI, confidence interval.
tration of steroids or tocolytics, latency period, and
cesarean section (Table IV).
DISCUSSION
Based on the studies demonstrating that antibiotic
prophylaxis reduces the incidence of early neonatal
group B streptococcal disease,9-1e we initiated a
policy of routine intrapartum prophylaxis for pre-
sumptive group B streptococcal colonization with
intravenous ampicillin in all patients with preterm
PROM in January 1990. Subsequently, both the
ACOG1 and AAP 14 have passed recommendations
endorsing this practice. This policy did not result
in a reduction in the incidence of blood culture-
proven neonatal sepsis. We found, however, that
after the change in policy, postpartum endomyo-
metritis was occurring more often. This resulted in
concern that the universal use of ampicillin for
group B streptococcal prophylaxis may lead to un-
desired effects on the maternal and fetal bacterial
flora.
Prophylactic antibiotic therapy in patients with
preterm PROM has not been shown to reduce the
prevalence of blood culture-proven neonatal sep-
sis3-6 and postpartum endomyometritis,z-4,6 Amon
TABLE 4. Multivariate analysis of risk factors for
postpartum endomyometritis
Odds ratio 95% CI P
GADE 0.90 0.7--1.1 0.4
BW 1.00 0.9-1.0 0.6
Received steroids 1.20 0.3-4.3 0.8
Received tocolytics 2.00 1.0-4. <0.05
PROM,AT 0.80 0.6-0.9 <0.02
Cesarean section 12.60 5.1-30.8 <0.00
Received ampicillin 9.30 3.8-22.5 <0.001
aFactors entered into the regression from top to bottom. CI, confi-
dence interval.
et al.z reported a lower prevalence of neonatal in-
fectious complications in patients treated with am-
picillin prophylaxis (1/42) vs. placebo (6/36). They
also showed a trend toward a decreased prevalence
of neonatal and perinatal mortality, and a trend to-
ward an increased prevalence in postpartum endo-
metritis. Johnston and coworkerss have demon-
strated a lower prevalence of endomyometritis in
patients treated with mezlocillin initially and am-
picillin until delivery. Conversely, McDuffie et
al. is have reported a case series of adverse perinatal
outcome associated with the development of resis-
tant Enterobacteriaceae after ampicillin or amoxi-
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cillin prophylaxis in patients with preterm PROM.
In 2 of the 4 cases described, the patients devel-
oped postpartum endomyometritis and pelvic vein
thrombophlebitis. Prophylactic antibiotics have,
however, been shown to prolong the latency period
in patients with preterm PROM.z-6 This has led to
fewer infants being admitted to an intensive care
nursery and a lower incidence of neonatal respira-
tory complications.
Abdominal delivery is a predisposing factor to
the development of postpartum endomyometritis.
Work by Gonik et al. 16 supports the hypothesis that
incipient infection at the time of cesarean delivery
may limit the effectiveness of antimicrobial pro-
phylaxis and predispose the patient to develop
postpartum infection. Watts et al. 17 demonstrated
that the isolation of group B streptococcus or
terococcus faecalis from the upper genital tract prior
to cesarean delivery was significantly associated
with postpartum endomyometritis. They found
that group B streptococcus was susceptible to the
prophylactic agents used, suggesting that virulence
factors other than antibiotic resistance may be im-
portant in the development of postpartum infec-
tious morbidity.
We found a higher prevalence of sepsis in the
infants of patients who experienced ruptured
membranes and delivery earlier in gestation. As
suggested by Morales and Lira, lz inhibition of
group B streptococcal infection by amniotic fluid
may be more effective with advancing gestational
age, therefore affording greater protection to more
advanced gestations. Immaturity itself may predis-
pose the neonate to the development of bacterial
sepsis. In our study, the latency period between
premature PROM and delivery was also prolonged
in the neonates who developed sepsis. This may
represent a group of patients in whom a short
course of ampicillin merely masked an underlying
subclinical intra-amniotic infection. The antibiotics
may not have achieved adequate, sustained con-
centrations to eradicate the bacteria, resulting in a
prolonged latency period. The effect of a short
course of antibiotics on the maternal bacterial flora
and possible development of resistant or more viru-
lent strains have not been fully investigated.
Postpartum endomyometritis occurred in 50% of
our patients receiving antibiotic prophylaxis. This
rate is much higher than the expected 3% after
vaginal delivery and 12-51% after cesarean section
at term.4 Antibiotic prophylaxis at time of cesarean
delivery has decreased the risk of postpartum en-
dometritis, however, prophylactic failures do occur.
After having received a short course of antibiotic
prophylaxis the vaginal bacterial flora may be al-
tered, leading to a resistant species of bacteria
which then would cause ascending infection after
delivery. Even after controlling for route of deliv-
ery, gestational age at delivery, birth weight, and
latency period, we found that antibiotic prophy-
laxis predisposes the patient to the development of
postpartum infection.
Amstcy and Gibbs is have proposed that penicil-
lin G with its narrower and more specific spectrum
of activity against group B streptococcus is a better
choice than ampicillin for prophylaxis. However,
further research into how various group B strepto-
coccal virulence factors are modified by antibiotics,
the duration of therapy necessary in colonized pa-
tients with preterm PROM, and whether resistant
bacterial strains will develop is necessary before
definitive recommendations are offered.
In summary, a policy of universal treatment with
ampicillin for Group B streptococcus prophylaxis
resulted in an increased risk of postpartum endo-
myometritis without a clear reduction in the preva-
lence of neonatal sepsis.
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